InMed Pharmaceuticals Inc.
MTRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 7 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesINM
Key figures
- Market capClose on Nov 6, 2026
- $8.55M
- Insider buysLast 90 days, $238.4K in total
- 7
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$12.6M
- No comparable prior period
- Free cash flow, FY2026
- –
- No comparable prior period
- Revenue, Q1 FY2027
- –
- No comparable prior period
Superinvestors holding MTRI, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MTRI at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by InMed Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 (view filing)8:18 PM ET | Nov 5 | 4 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +2.64K | $13.10 | +$34.6K | +2.8%98.3K after | |
| Oct 27, 2026 (view filing)2:13 PM ET | Oct 23 | 4 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +4 | $1.32 | +$5.28 | 0.0%956.6K after | |
| Oct 20, 2026 (view filing)5:31 PM ET | Oct 16-19 | 4 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +1.09K | $1.32 | +$1.43K | +0.1%956.6K after | 2 lots |
| Oct 15, 2026 (view filing)4:39 PM ET | Oct 13-15 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +9.57K | $1.33 | +$12.7K | +1.0%955.5K after | 3 lots |
| Oct 8, 2026 (view filing)6:27 PM ET | Oct 6-8 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +10.9K | $1.33 | +$14.5K | +1.2%945.9K after | 3 lots |
| Oct 5, 2026 (view filing)5:11 PM ET | Oct 1-5 | 4 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +42.9K | $1.33 | +$57.1K | +4.8%935.0K after | 3 lots |
| Sep 16, 2026 (view filing)6:58 PM ET | Sep 14-16 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +91.1K | $1.30 | +$118.1K | +11.4%892.1K after | 3 lots |
| Jul 17, 2026 (view filing)7:29 PM ET | Jul 15 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +1.00K | $1.56 | +$1.55K | +0.1%801.0K after | |
| Jul 16, 2026 (view filing)9:58 PM ET | Jul 14-16 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +20.5K | $1.55 | +$31.8K | +37.7%75.0K after | 6 lots |
| Jul 2, 2026 (view filing)7:02 PM ET | Jun 30-Jul 2 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +6.55K | $1.55 | +$10.1K | +9.8%73.1K after | 6 lots |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in InMed Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding MTRI in 13F filings for Q2 2026.